デフォルト表紙
市場調査レポート
商品コード
1760640

点鼻インフルエンザワクチンの世界市場レポート (2025年)

Nasal Spray Influenza Vaccine Global Market Report 2025


出版日
ページ情報
英文 175 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
点鼻インフルエンザワクチンの世界市場レポート (2025年)
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

点鼻インフルエンザワクチンの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.1%で24億3,000万米ドルに成長します。予測期間中の成長は、簡便な予防接種に対する需要の高まり、季節性インフルエンザ患者の増加、政府の取り組みや支援の強化、高齢者やハイリスク人口の増加予測、医療環境におけるワクチンの採用拡大などの要因によって牽引されると予想されます。この期間の主な動向としては、ワクチン送達システムの革新、粘膜免疫戦略の統合、ウイルスベクター・プラットフォームの技術的進歩、コールドチェーン技術の進歩、mRNA技術の導入などが挙げられます。

インフルエンザの流行が拡大していることから、点鼻インフルエンザワクチン市場は今後牽引役となることが予想されます。インフルエンザは感染力の強いウイルス感染症で、主に呼吸器系を侵し、発熱、咳、喉の痛み、体の痛み、疲労などの症状を引き起こします。インフルエンザ患者の増加は、ウイルスの頻繁な遺伝子変異によるところが大きく、既存の免疫から逃れ、集団の中で急速に広がることを可能にしています。点鼻インフルエンザワクチンは、通常ウイルスが侵入する鼻腔に弱毒化したウイルスを直接送り込み、免疫反応を促すことで、ウイルスから身を守るのに役立ちます。例えば、2024年6月、英国健康安全保障局は、2022年第40週から2023年第15週の間に、イングランドの108のNHSトラストによって1,681件のインフルエンザ関連重症患者入院が確認されたと報告しました。これは、前シーズンの182件に比べ大幅な増加でした。その結果、インフルエンザの流行が拡大し、点鼻インフルエンザワクチン市場の拡大に寄与しています。

点鼻インフルエンザワクチン市場で事業を展開する企業は、免疫反応を高め、患者のアドヒアランスを向上させるため、弱毒生インフルエンザワクチン(LAIV)などの革新的な製剤の開発に注力しています。弱毒化インフルエンザ生ワクチンは、免疫系を刺激して抗体を産生させる弱毒化した生きたウイルスから作られ、病気を引き起こすことなく予防効果を発揮します。この種のワクチンは、局所免疫と全身免疫の両方を通じてより強力な免疫反応を生み出し、将来のインフルエンザ感染に対する身体の防御力を高める。例えば、2024年9月、アストラゼネカは弱毒生インフルエンザ・ワクチン(LAIV)であるFluMistの承認を米国食品医薬品局(FDA)から取得しました。このワクチンは、49歳までの成人の自己投与、または2歳から17歳までの小児への介護者による投与が可能であり、自己投与または介護者による投与が承認された米国初のインフルエンザワクチンとなります。今回の承認は、参加者の100%が指示通りに全量を接種できたという広範な使用性試験を受けたものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場のマクロ経済シナリオ:金利・インフレ・地政学・貿易戦争・関税・コロナ禍と回復が市場に及ぼす影響を含む

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の点鼻インフルエンザワクチン市場:PESTEL分析(政治・社会・技術・環境・法的要因、促進要因、抑制要因)
  • 最終用途産業の分析
  • 世界の点鼻インフルエンザワクチン市場:成長率分析
  • 世界の点鼻インフルエンザワクチンの市場規模・成長率:実績値、2019~2024年
  • 世界の点鼻インフルエンザワクチンの市場規模・成長率:予測値、2024~2029年、2034年
  • 世界の点鼻インフルエンザワクチン市場:総有効市場(TAM)

第6章 市場セグメンテーション

  • 世界の点鼻インフルエンザワクチン市場:種類別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 生弱毒化インフルエンザワクチン(LAIV)
  • 不活化インフルエンザワクチン
  • 世界の点鼻インフルエンザワクチン市場:投与方法別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 単回投与
  • 多回投与
  • 世界の点鼻インフルエンザワクチン市場:年齢層別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 小児科
  • 成人用
  • 高齢者
  • 世界の点鼻インフルエンザワクチン市場:流通チャネル別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 病院
  • クリニック
  • 薬局
  • オンラインストア
  • その他の流通チャネル
  • 世界の点鼻インフルエンザワクチン市場:エンドユーザー別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 医療提供者
  • 個人
  • 政府保健当局
  • 製薬企業
  • 世界の点鼻インフルエンザワクチン市場:生弱毒化インフルエンザワクチン(LAIV)の種類別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 三価生弱毒化インフルエンザワクチン(三価LAIV)
  • 四価生弱毒化インフルエンザワクチン(四価LAIV)
  • 世界の点鼻インフルエンザワクチン市場:不活化インフルエンザワクチンの種類別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 全ウイルス不活化ワクチン
  • スプリットウイルス不活化ワクチン
  • サブユニット不活化ワクチン
  • アジュバント添加不活化ワクチン
  • 高用量不活化ワクチン

第7章 地域別・国別の分析

  • 世界の点鼻インフルエンザワクチン市場:地域別、実績値・予測値、2019~2024年、2024~2029年、2034年
  • 世界の点鼻インフルエンザワクチン市場:国別、実績値・予測値、2019~2024年、2024~2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 点鼻インフルエンザワクチン市場:競合情勢
  • 点鼻インフルエンザワクチン市場:企業プロファイル
    • Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • GSK plc Overview, Products and Services, Strategy and Financial Analysis
    • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
    • CSL Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Sinovac Biotech Ltd.
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
  • NPO Microgen JSC
  • Changchun BCHT Biotechnology Co. Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • FluGen Inc.
  • BioDiem Ltd
  • Starpharma Holdings Limited
  • Codagenix Inc.
  • Nobilon International B.V.
  • KM Biologics Co. Ltd.
  • Altimmune Inc.
  • Mylab Discovery Solutions Private Limited

第32章 世界市場:競合ベンチマーキング・ダッシュボード

第33章 主要な企業合併・買収 (M&A)

第34章 最近の市場動向

第35章 市場の潜在力の高い国・部門と戦略

  • 点鼻インフルエンザワクチン市場:最新機会を提供する国(2029年)
  • 点鼻インフルエンザワクチン市場:最新機会を提供する部門(2029年)
  • 点鼻インフルエンザワクチン市場:成長戦略(2029年)
    • 市場動向に基づく戦略
    • 競争戦略

第36章 付録

目次
Product Code: r35517

The nasal spray influenza vaccine is a needle-free flu vaccine delivered through the nose, utilizing live attenuated viruses to provide protection against seasonal influenza. It is administered by spraying into the nostrils, where it triggers an immune response in the nasal passages to defend against the flu.

The primary types of nasal spray influenza vaccines are the live attenuated influenza vaccine (LAIV) and the inactivated influenza vaccine. LAIV is a needle-free flu vaccine that uses weakened live viruses to stimulate strong systemic and mucosal immune responses. These vaccines can be administered in single-dose or multi-dose formats and are designed for various age groups, including children, adults, and older adults. Distribution channels include hospitals, clinics, pharmacies, online stores, and other points of sale. End users of nasal spray influenza vaccines consist of healthcare providers, individuals, government health agencies, and pharmaceutical companies.

The nasal spray influenza vaccines market research report is one of a series of new reports from The Business Research Company that provides nasal spray influenza vaccines market statistics, including nasal spray influenza vaccines industry global market size, regional shares, competitors with a nasal spray influenza vaccines market share, nasal spray influenza vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the nasal spray influenza vaccines industry. This nasal spray influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nasal spray influenza vaccine market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to factors such as improved vaccine accessibility, heightened awareness of flu prevention, a growing emphasis on pediatric vaccination, higher vaccination rates, and a greater preference for needle-free vaccines.

The nasal spray influenza vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during the forecast period is expected to be driven by factors such as a rising demand for convenient immunization, an increase in seasonal influenza cases, more government initiatives and support, projected growth in geriatric and high-risk populations, and greater adoption of vaccines in healthcare settings. Key trends during this period include innovations in vaccine delivery systems, the integration of mucosal immunity strategies, technological advancements in viral vector platforms, progress in cold-chain technology, and the incorporation of mRNA technology.

The growing prevalence of influenza is expected to drive the market for nasal spray influenza vaccines in the future. Influenza is a highly contagious viral infection that mainly affects the respiratory system, causing symptoms such as fever, cough, sore throat, body aches, and fatigue. The rise in influenza cases is largely due to the frequent genetic mutations of the virus, allowing it to escape existing immunity and spread quickly through populations. The nasal spray influenza vaccine helps protect against the virus by delivering a weakened form directly into the nasal passages, where the virus typically enters, prompting an immune response. For example, in June 2024, the UK Health Security Agency reported that between week 40 of 2022 and week 15 of 2023, 1,681 confirmed influenza-related critical care admissions were recorded by 108 NHS trusts in England. This was a significant increase compared to 182 admissions the previous season. As a result, the growing prevalence of influenza is contributing to the expansion of the nasal spray influenza vaccine market.

Companies operating in the nasal spray influenza vaccine market are focusing on creating innovative formulations, such as live attenuated influenza vaccines (LAIV), to enhance immune response and improve patient adherence. A live attenuated influenza vaccine is made from live, weakened viruses that stimulate the immune system to produce antibodies, offering protection without causing the disease. This type of vaccine generates a stronger immune response through both local and systemic immunity, which boosts the body's defense against future flu infections. For example, in September 2024, AstraZeneca received approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV). This vaccine can be self-administered by adults up to 49 years old or administered by caregivers to children between 2 and 17 years old, making it the first influenza vaccine in the U.S. approved for self- or caregiver-administration. The approval followed extensive usability studies that showed 100% of participants successfully delivered the full dose as instructed.

In October 2023, Mylab Discovery Solutions, an India-based biotechnology company, partnered with the Serum Institute of India to launch Nasovac S4, India's first nasal influenza vaccine. Through this collaboration, the two companies aim to provide comprehensive protection against various influenza strains with Nasovac S4, a needle-free nasal vaccine. Serum Institute of India is a biotechnology company specializing in nasal influenza vaccines such as Nasovac-S and Nasovac-S4.

Major players in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited

North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nasal spray influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nasal spray influenza vaccine market consists of sales of flumist quadrivalent, fluenz tetra, vaxinate, centripetal flu nasal spray vaccine, nasovac-s, fluvac nasal spray, and live attenuated influenza vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nasal Spray Influenza Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nasal spray influenza vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nasal spray influenza vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nasal spray influenza vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Live Attenuated Influenza Vaccine (LAIV); Inactivated Influenza Vaccine
  • 2) By Administration Method: Single-Dose Administration; Multi-Dose Administration
  • 3) By Age Group: Pediatric; Adult; Geriatric
  • 4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Online Stores; Other Distribution Channels
  • 5) By End User: Healthcare Providers; Individuals; Government Health Departments; Pharmaceutical Companies
  • Subsegments:
  • 1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV); Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
  • 2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Subunit Inactivated Vaccine; Adjuvanted Inactivated Vaccine; High-Dose Inactivated Vaccine
  • Companies Mentioned: Sanofi Pasteur SA; AstraZeneca PLC; GSK plc; Moderna Inc.; CSL Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nasal Spray Influenza Vaccine Market Characteristics

3. Nasal Spray Influenza Vaccine Market Trends And Strategies

4. Nasal Spray Influenza Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nasal Spray Influenza Vaccine Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nasal Spray Influenza Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nasal Spray Influenza Vaccine Market Growth Rate Analysis
  • 5.4. Global Nasal Spray Influenza Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nasal Spray Influenza Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nasal Spray Influenza Vaccine Total Addressable Market (TAM)

6. Nasal Spray Influenza Vaccine Market Segmentation

  • 6.1. Global Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Live Attenuated Influenza Vaccine (LAIV)
  • Inactivated Influenza Vaccine
  • 6.2. Global Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single-Dose Administration
  • Multi-Dose Administration
  • 6.3. Global Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric
  • Adult
  • Geriatric
  • 6.4. Global Nasal Spray Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Pharmacies
  • Online Stores
  • Other Distribution Channels
  • 6.5. Global Nasal Spray Influenza Vaccine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Healthcare Providers
  • Individuals
  • Government Health Departments
  • Pharmaceutical Companies
  • 6.6. Global Nasal Spray Influenza Vaccine Market, Sub-Segmentation Of Live Attenuated Influenza Vaccine (LAIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV)
  • Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
  • 6.7. Global Nasal Spray Influenza Vaccine Market, Sub-Segmentation Of Inactivated Influenza Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Virus Inactivated Vaccine
  • Split Virus Inactivated Vaccine
  • Subunit Inactivated Vaccine
  • Adjuvanted Inactivated Vaccine
  • High-Dose Inactivated Vaccine

7. Nasal Spray Influenza Vaccine Market Regional And Country Analysis

  • 7.1. Global Nasal Spray Influenza Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nasal Spray Influenza Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nasal Spray Influenza Vaccine Market

  • 8.1. Asia-Pacific Nasal Spray Influenza Vaccine Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nasal Spray Influenza Vaccine Market

  • 9.1. China Nasal Spray Influenza Vaccine Market Overview
  • 9.2. China Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nasal Spray Influenza Vaccine Market

  • 10.1. India Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nasal Spray Influenza Vaccine Market

  • 11.1. Japan Nasal Spray Influenza Vaccine Market Overview
  • 11.2. Japan Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nasal Spray Influenza Vaccine Market

  • 12.1. Australia Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nasal Spray Influenza Vaccine Market

  • 13.1. Indonesia Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nasal Spray Influenza Vaccine Market

  • 14.1. South Korea Nasal Spray Influenza Vaccine Market Overview
  • 14.2. South Korea Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nasal Spray Influenza Vaccine Market

  • 15.1. Western Europe Nasal Spray Influenza Vaccine Market Overview
  • 15.2. Western Europe Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nasal Spray Influenza Vaccine Market

  • 16.1. UK Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nasal Spray Influenza Vaccine Market

  • 17.1. Germany Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nasal Spray Influenza Vaccine Market

  • 18.1. France Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nasal Spray Influenza Vaccine Market

  • 19.1. Italy Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nasal Spray Influenza Vaccine Market

  • 20.1. Spain Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nasal Spray Influenza Vaccine Market

  • 21.1. Eastern Europe Nasal Spray Influenza Vaccine Market Overview
  • 21.2. Eastern Europe Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nasal Spray Influenza Vaccine Market

  • 22.1. Russia Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nasal Spray Influenza Vaccine Market

  • 23.1. North America Nasal Spray Influenza Vaccine Market Overview
  • 23.2. North America Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nasal Spray Influenza Vaccine Market

  • 24.1. USA Nasal Spray Influenza Vaccine Market Overview
  • 24.2. USA Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nasal Spray Influenza Vaccine Market

  • 25.1. Canada Nasal Spray Influenza Vaccine Market Overview
  • 25.2. Canada Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nasal Spray Influenza Vaccine Market

  • 26.1. South America Nasal Spray Influenza Vaccine Market Overview
  • 26.2. South America Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nasal Spray Influenza Vaccine Market

  • 27.1. Brazil Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nasal Spray Influenza Vaccine Market

  • 28.1. Middle East Nasal Spray Influenza Vaccine Market Overview
  • 28.2. Middle East Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nasal Spray Influenza Vaccine Market

  • 29.1. Africa Nasal Spray Influenza Vaccine Market Overview
  • 29.2. Africa Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nasal Spray Influenza Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Nasal Spray Influenza Vaccine Market Competitive Landscape
  • 30.2. Nasal Spray Influenza Vaccine Market Company Profiles
    • 30.2.1. Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GSK plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. CSL Limited Overview, Products and Services, Strategy and Financial Analysis

31. Nasal Spray Influenza Vaccine Market Other Major And Innovative Companies

  • 31.1. Sinovac Biotech Ltd.
  • 31.2. Emergent BioSolutions Inc.
  • 31.3. Serum Institute of India Pvt. Ltd.
  • 31.4. Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
  • 31.5. NPO Microgen JSC
  • 31.6. Changchun BCHT Biotechnology Co. Ltd.
  • 31.7. Mitsubishi Tanabe Pharma Corporation
  • 31.8. FluGen Inc.
  • 31.9. BioDiem Ltd
  • 31.10. Starpharma Holdings Limited
  • 31.11. Codagenix Inc.
  • 31.12. Nobilon International B.V.
  • 31.13. KM Biologics Co. Ltd.
  • 31.14. Altimmune Inc.
  • 31.15. Mylab Discovery Solutions Private Limited

32. Global Nasal Spray Influenza Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nasal Spray Influenza Vaccine Market

34. Recent Developments In The Nasal Spray Influenza Vaccine Market

35. Nasal Spray Influenza Vaccine Market High Potential Countries, Segments and Strategies

  • 35.1 Nasal Spray Influenza Vaccine Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nasal Spray Influenza Vaccine Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nasal Spray Influenza Vaccine Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer